Arvinas, Inc. reported positive topline results from its Phase 3 VERITAC-2 trial for vepdegestrant, supporting global regulatory filings aimed at treating metastatic breast cancer. The company also ...
AnaptysBio, Inc. announced positive Phase 2b trial results for its lead drug, rosnilimab, which targets PD-1+ T cells for rheumatoid arthritis (RA), and will present updated data in June 2025. Initial ...
The MarketWatch News Department was not involved in the creation of this content. Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene ...
Corvus Pharmaceuticals (CRVS) is in the process of evaluating the use of its interleukin-2-inducible T cell kinase [ITK] inhibitor for the treatment of patients with a wide variety of lymphoma types, ...
“The positive results of the Phase 3 VERIFY study across the primary and all key secondary endpoints provide compelling evidence of the potential for rusfertide as a first-in-class ...
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or ...
Immutep ( (IMMP)) has issued an announcement. On 22 December 2025, Immutep reported positive initial results from a placebo-controlled, double-blind first-in-human Phase I trial of IMP761, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback